Cargando…

Circulating tumor DNA profile and its clinical significance in patients with hormone receptor-positive and HER2-negative mBC

BACKGROUND: After early-line (first- and second-line) endocrine therapy, hormone-receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancers (mBCs) become resistant to endocrine therapy. Genetic alterations may underlie resistance to endocrine therap...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tang, Yu, Li, Jing, Liu, Binliang, Ran, Jialu, Hu, Zhe-Yu, Ouyang, Quchang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9742482/ https://www.ncbi.nlm.nih.gov/pubmed/36518248 http://dx.doi.org/10.3389/fendo.2022.1075830

Ejemplares similares

Real-world treatment in patients with HER2+ metastatic breast cancer: Treatment decisions in HER2+ mBC
por: Colomer, R., et al.
Publicado: (2017)

The circulating tumor DNA (ctDNA) alteration level predicts therapeutic response in metastatic breast cancer: Novel prognostic indexes based on ctDNA
por: Liu, Binliang, et al.
Publicado: (2022)

Efficacy of Fulvestrant in Women with Hormone-Resistant Metastatic Breast Cancer (mBC): A Canadian Province Experience †
por: Andrahennadi, Samitha, et al.
Publicado: (2021)

Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER‐targeted therapy in HER2 amplification‐positive and HER2 mutation‐positive amplification‐negative patients
por: Liu, Binliang, et al.
Publicado: (2022)

Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry
por: Gampenrieder, Simon Peter, et al.
Publicado: (2021)

Pyrotinib in combination with letrozole for hormone receptor-positive, human epidermal growth factor receptor 2-positive metastatic breast cancer (PLEHERM): a multicenter, single-arm, phase II trial
por: Hu, Zhe-Yu, et al.
Publicado: (2023)

Retrospective Observational Study of Outcomes in HER2-Positive Metastatic Breast Cancer (mBC) Patients Treated with Ado-Trastuzumab Emtansine (T-DM1) and Subsequent Treatments After T-DM1 in the United States
por: Denduluri, Neelima, et al.
Publicado: (2022)

The Long Non-Coding BC200 Is a Novel Circulating Biomarker of Parathyroid Carcinoma
por: Morotti, Annamaria, et al.
Publicado: (2022)

Dual HER2 blockade with pertuzumab (P) and trastuzumab (T) in patients with HER2-positive metastatic breast cancer (mBC) relapsing after adjuvant treatment with T: results from a German non-interventional study (NIS) HELENA (NCT01777958)
por: Thill, Marc, et al.
Publicado: (2022)

Subtyping of metastatic breast cancer based on plasma circulating tumor DNA alterations: An observational, multicentre platform study
por: Hu, Zhe-Yu, et al.
Publicado: (2022)

Clinicopathological characteristics, evolution, treatment pattern and outcomes of hormone-receptor-positive/HER2-low metastatic breast cancer
por: You, Shuhui, et al.
Publicado: (2023)

Immunomodulatory effects of metronomic vinorelbine (mVRL), with or without metronomic capecitabine (mCAPE), in hormone receptor positive (HR+)/HER2-negative metastatic breast cancer (MBC) patients: final results of the exploratory phase 2 Victor-5 study
por: Pepe, F. F., et al.
Publicado: (2022)

Efficacy and safety of trastuzumab emtansine (T-DM1) in the treatment of HER2-positive metastatic breast cancer (MBC): a meta-analysis of randomized controlled trial
por: Yan, Hongjing, et al.
Publicado: (2017)

Single Hormone Receptor-Positive Metaplastic Breast Cancer: Similar Outcome as Triple-Negative Subtype
por: Mao, Jinqian, et al.
Publicado: (2021)

Evaluation of hormonal and circulating inflammatory biomarker profiles in the year following bariatric surgery
por: Kim, Eun Ran, et al.
Publicado: (2023)

Complete response to pyrotinib combined with letrozole as first-line treatment of HER2-positive/HR-positive breast cancer: a case report
por: Xie, Ning, et al.
Publicado: (2021)

Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: results of a phase II trial (AGMT MBC-6)
por: Rinnerthaler, Gabriel, et al.
Publicado: (2021)

21-Gene Recurrence Assay Associated With Favorable Metabolic Profiles in HR-Positive, HER2-Negative Early-Stage Breast Cancer Patients
por: Zhu, Yifei, et al.
Publicado: (2021)

ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC)
por: Ferrando, Lorenzo, et al.
Publicado: (2023)

Adjuvant tamoxifen for male breast cancer (MBC).
por: Ribeiro, G., et al.
Publicado: (1992)

Editorial: The effects of circulating non-sex hormones in cardiovascular disease
por: Shan, Su-Kang, et al.
Publicado: (2022)

Circulating Biomarkers of CDK4/6 Inhibitors Response in Hormone Receptor Positive and HER2 Negative Breast Cancer
por: Migliaccio, Ilenia, et al.
Publicado: (2021)

Role of aerobic exercise in ameliorating NASH: Insights into the hepatic thyroid hormone signaling and circulating thyroid hormones
por: Liu, Qiuhong, et al.
Publicado: (2022)

Corrigendum: Role of aerobic exercise in ameliorating NASH: Insights into the hepatic thyroid hormone signaling and circulating thyroid hormones
por: Liu, Qiuhong, et al.
Publicado: (2023)

Correlation of Significantly Decreased Serum Circulating Mesencephalic Astrocyte-Derived Neurotrophic Factor Level With an Increased Risk of Future Cardiovascular Disease in Adult Patients With Growth Hormone Deficiency
por: Ren, Ziyu, et al.
Publicado: (2021)

Role of sex hormones in diabetic nephropathy
por: Liu, Jiahui, et al.
Publicado: (2023)

Role of HER3 expression and PTEN loss in patients with HER2-overexpressing metastatic breast cancer (MBC) who received taxane plus trastuzumab treatment
por: Park, Y H, et al.
Publicado: (2014)

MBC and ECBL libraries: outstanding tools for drug discovery
por: Ginex, Tiziana, et al.
Publicado: (2023)

Epithelial-Mesenchymal-Transition-Like Circulating Tumor Cell-Associated White Blood Cell Clusters as a Prognostic Biomarker in HR-Positive/HER2-Negative Metastatic Breast Cancer
por: Guan, Xiuwen, et al.
Publicado: (2021)

Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancer
por: Yi, Zongbi, et al.
Publicado: (2020)

The Retinol Circulating Complex Releases Hormonal Ligands During Acute Stress Disorders
por: Ingenbleek, Yves
Publicado: (2018)

Clinical Parameters of Silent Corticotroph Adenomas With Positive and Negative Adrenocorticotropic Hormone Immunostaining: A Large Retrospective Single-Center Study of 105 Cases
por: Zhang, Keyi, et al.
Publicado: (2021)

TRLS-06. PHASE 1 EXPANSION STUDY OF IRINOTECAN LIPOSOME INJECTION (nal-IRI) IN PATIENTS WITH METASTATIC BREAST CANCER (mBC): FINDINGS FROM THE COHORT WITH ACTIVE BRAIN METASTASIS (BM)
por: Anders, Carey, et al.
Publicado: (2019)

Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens
por: Dai, Ming Shen, et al.
Publicado: (2021)

Survival-Associated Metabolic Genes and Risk Scoring System in HER2-Positive Breast Cancer
por: Gao, Chundi, et al.
Publicado: (2022)

Serum Anti-Müllerian Hormone Is Significantly Altered by Downregulation With Daily Gonadotropin-Releasing Hormone Agonist: A Prospective Cohort Study
por: Drakopoulos, Panagiotis, et al.
Publicado: (2019)

HER2-positive double primary tumor of gastric and breast cancer occur synchronously in a patient: A case report
por: OUYANG, QUCHANG, et al.
Publicado: (2016)

The Effect of Early Life Exposure to Triclosan on Thyroid Follicles and Hormone Levels in Zebrafish
por: Tang, Ning, et al.
Publicado: (2022)

Correspondence: Confirmation of Uterotrophic Activity for 4-MBC in the Immature Rat
por: Ashby, J
Publicado: (2001)

Advancements in the Treatment of Metastatic Breast Cancer (MBC): The Role of Ixabepilone
por: Cristofanilli, Massimo
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_6s9jntincdt5t2lad098kt9qm1